World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access
Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc
Journal website http://www.wjon.org

Case Report

Volume 5, Number 5-6, December 2014, pages 223-227

Pazopanib-Induced Regression of Brain Metastasis After Whole Brain Palliative Radiotherapy in Metastatic Renal Cell Cancer Progressing on First-Line Sunitinib: A Case Report

Figures

Figure 1.
Figure 1. Patient developed response after first-line sunitinib therapy with complete resolution of (A) hilar lymphadenopathy (yellow arrow) and more than 50% reduction in size of (B) lung metastasis (yellow arrow).
Figure 2.
Figure 2. Patient developed response after pazopanib (800 mg/day) with resolution of brain metastasis. (A) Coronal T1-weighted scan with gadolinium contrast demonstrating small sub-centimeter contrast enhancing lesions (yellow arrow) on baseline MRI scan (left panel) that resolved after 3 months of pazopanib (right panel). (B) Axial T1-weighted baseline MRI scan with gadolinium showing small sub-centimeter metastasis (left panel) that resolved after 3 months of pazopanib (right panel).
Figure 3.
Figure 3. Patient developed response after re-challenge schedule of reduced-dose pazopanib (600 mg/day) with reduction in size of left parietal brain metastasis. (A) Coronal T1-weighted scan with gadolinium contrast demonstrating contrast enhancing lesions (yellow arrow) on baseline MRI scan (left panel) in left parietal region that resolved after 3 months of pazopanib (right panel). (B) Axial T1-weighted baseline MRI scan with gadolinium showing left parietal metastasis (left panel) that resolved after 3 months of pazopanib (right panel).